Multiple batches of substandard medical imaging contrast agents have been identified across global markets, prompting a worldwide safety alert from the World Health Organization after initial detection in Ireland. The Health Products Regulatory Authority (HPRA) of Ireland reported the compromised products to WHO in March 2026, triggering coordinated international surveillance efforts.
Key takeaways
- Three major contrast agent brands — ACCUPAQUE, OMNIPAQUE, and VISIPAQUE — contain substandard formulations in 100ml containers
- Products were first detected by Ireland’s regulatory authority and reported to WHO in March 2026
- Global health authorities across all WHO regions are now conducting market surveillance
International Detection and Response
The contaminated products include ACCUPAQUE (iohexol), OMNIPAQUE (iohexol), and VISIPAQUE (iodixanol) solutions for injection, all packaged in 100ml polypropylene containers. According to Nigeria’s National Agency for Food and Drugs Administration and Control (NAFDAC), the initial identification occurred through routine quality monitoring in Ireland.
The WHO alert system activated immediately after HPRA’s March 2026 notification, enabling rapid communication to regulatory authorities across all six WHO regions. This represents a critical test of global pharmaceutical surveillance networks established following previous contamination incidents.
WHO Regional Response to Contrast Agent Alert
Global coordination across six WHO regions, March 2026
Source: WHO, NAFDAC, 2026 | Georgian Medical Journal News
Clinical Safety Implications
Contrast agents are essential for medical imaging procedures including CT scans, angiography, and various interventional radiology procedures. Substandard formulations pose immediate patient safety risks through potential allergic reactions, inadequate imaging quality, or unknown chemical impurities.
Healthcare facilities worldwide use these specific products for diagnostic imaging, making the geographic scope of potential exposure substantial. The FDA’s medical device safety monitoring system and equivalent agencies globally are coordinating batch tracking efforts. For more context on medication quality and safety issues, international regulatory cooperation remains essential.
Multiple batches of three major contrast imaging agents have been identified as substandard across global markets, requiring immediate healthcare provider vigilance
— Health Products Regulatory Authority, Ireland (WHO Alert, March 2026)
What this means
Frequently asked questions
Which specific contrast agents are affected?
ACCUPAQUE (iohexol), OMNIPAQUE (iohexol), and VISIPAQUE (iodixanol) in 100ml polypropylene containers have been identified as substandard. Healthcare providers should verify batch numbers with local regulatory authorities.
How were these substandard products detected?
Ireland’s Health Products Regulatory Authority identified the compromised products through routine quality monitoring and reported findings to WHO in March 2026. This triggered the global alert system across all WHO regions.
What should patients do if they recently received contrast imaging?
Patients should contact their healthcare provider if they experience any unusual symptoms following recent imaging procedures. Most contrast procedures are completed safely, but any concerns warrant medical consultation.
The detection underscores the critical importance of robust pharmaceutical quality monitoring systems and rapid international communication networks. As imaging procedures continue globally, coordinated surveillance efforts between regulatory authorities will determine the full scope of affected products and prevent further patient exposure.
Was this article helpful?
Related Coverage
